Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

NCT04917744 ·Status: COMPLETED

Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.

NCT04573933 ·Status: COMPLETED

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560 ·Status: TERMINATED ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

NCT04152941 ·Status: COMPLETED

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

NCT05410015 ·Status: RECRUITING

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

NCT06588322 ·Status: RECRUITING ·Phase: NA

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212 ·Status: COMPLETED ·Phase: PHASE2

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

NCT05763472 ·Status: UNKNOWN

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

NCT02004093 ·Status: COMPLETED ·Phase: PHASE2

The Immune Landscape of Epithelial Ovarian Cancer

NCT05984875 ·Status: RECRUITING

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

NCT01456065 ·Status: UNKNOWN ·Phase: PHASE1

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

NCT01048814 ·Status: COMPLETED

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

NCT06572735 ·Status: RECRUITING

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

NCT06084195 ·Status: RECRUITING ·Phase: NA

Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy

NCT03491033 ·Status: COMPLETED

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

NCT06775470 ·Status: RECRUITING

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT02591095 ·Status: COMPLETED ·Phase: PHASE2

Genomic BRCA and Extensive ovArian Cancer Testing

NCT04027868 ·Status: COMPLETED

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

NCT04582552 ·Status: UNKNOWN

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

NCT00189579 ·Status: TERMINATED ·Phase: PHASE2

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

NCT01616303 ·Status: COMPLETED ·Phase: PHASE2

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

NCT05368207 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT00096993 ·Status: COMPLETED ·Phase: PHASE2